Mario Filion

This inventor holds 26 USPTO granted patents and 15 published patent applications, plus 7 CIPO patents and 11 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Alethia Biotherapeutics Inc., Adc Therapeutics Sa, Daiichi Sankyo Company, Limited. Active years: 2011-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mario Filion. Retrieved from https://idiyas.com/inventor/mario-filion

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 15)

% Patents Active = 80.8

CIPO Patents = 7 (Patent Applications = 16)

EPO Patents = 11 (Patent Applications = 18)

Average Co-Inventor Count = 3.1

ph-index = 7

Forward Citations = 110(Granted Patents)

Location History:

Quebec, CA (2012)
Longueuil, CA (2011 - 2021)

Company Filing History:

19 out of 19

Alethia Biotherapeutics Inc.

Daiichi Sankyo Company, Limited

patents

4. 1 out of 1,039

National Research Council of Canada

patents

where one patent can have more than one assignee

Years Active: 2011-2021

Loading Chart...

Areas of Expertise:

Breast Cancer Treatment

Kidney Associated Antigen

Siglec-15 Antibodies

Osteoclast Differentiation

Clusterin Inhibitors

Tumor Volume Reduction

Bone Remodeling

Polynucleotides

Antigen Binding Fragments

Cancer Treatment

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11084872 - Method for treating breast cancer (2021-08-10),

2. 10597450 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2020-03-24),

3. RE47672 - Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 (2019-10-28),

4. 9855291 - Anti-kidney associated antigen 1 (KAAG1) antibodies (2018-01-02),

5. 9828426 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2017-11-28),

6. 9822170 - Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer (2017-11-21),

7. 9695419 - Polynucleotides and polypeptide sequences involved in the process of bone remodeling (2017-07-04),

8. 9617337 - Siglec-15 antibodies in treating bone loss-related disease (2017-04-11),

9. 9512211 - Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume (2016-12-06),

10. 9493562 - Anti-Siglec-15 antibodies (2016-11-15),

11. 9393302 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2016-07-19),

12. 9388242 - Nucleic acids encoding anti-Siglec-15 antibodies (2016-07-12),

13. 9067984 - Methods of impairing osteoclast differentiation using antibodies that bind Siglec-15 (2015-06-30),

14. 9040246 - Methods of making antibodies that bind polypeptides involved in the process of bone remodeling (2015-05-26),

15. 8937163 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2015-01-20),

Title: Mario Filion - Innovative Inventor from Longueuil, CA

Introduction: Mario Filion is a renowned inventor hailing from Longueuil, Canada, known for his groundbreaking contributions to various industries.

Latest Patents: Mario Filion holds several patents in the fields of technology and engineering, with his most recent inventions focusing on sustainable energy solutions and advanced robotics.

Career Highlights: Throughout his illustrious career, Mario Filion has been recognized for his exceptional problem-solving skills and creative thinking, leading to the development of cutting-edge technologies that have revolutionized the way we live and work.

Collaborations: Mario Filion has collaborated with leading research institutions and tech companies to bring his innovative ideas to life, fostering a culture of innovation and excellence in the industry.

Conclusion: Mario Filion's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs, solidifying his legacy as a true pioneer in the world of technology.

Profile summary based on public USPTO records.